Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Stopped insufficient clinical response per DSMB
Conditions
- Hormone-Resistant Prostate Cancer
- Metastatic Prostate Carcinoma
- Stage IV Prostate Cancer
Interventions
- DIETARY_SUPPLEMENT: Ascorbic Acid
- DRUG: Docetaxel
- OTHER: Laboratory Biomarker Analysis
- OTHER: Pharmacological Study
- OTHER: Placebo
- OTHER: Quality-of-Life Assessment
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators